Skip to content
Pfizer logo

Pfizer

PFIZER NSE
₹3,856.00 +5.70 (+0.15%)
Market Cap
₹17,640 Cr
P/E
20.53
View as Markdown
MCP
Close 20 Nov 2026 ₹3,856.00 1Y −1,112.50 −22.4%
Start ₹4,968.50

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Standalone · TTM

ROCE
24.10%
Debt to Equity
0.04
EPS (TTM)
₹187.85
Book Value
₹958.74
Market Cap
₹17,640 Cr
P/E (TTM)
20.53
P/B
4.02
ROE
18.00%
Dividend Yield
1.95%
EBITDA
₹1,092 Cr
52W High
₹5,257.00
52W Low
₹3,589.00
Day Range
₹3,816.00 – ₹3,872.00
Volume
13,808

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

Pfizer peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
Pfizer (this company)
3,856.0020.5317,6404.021.95%18.00%24.10%2,654859
Median 8 companies2,089.7541.351,21,8404.690.70%17.25%19.15%22,7702,808

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

59 Good

Data confidence 100/100

Category scores

Quality
73
Strong
Returns, margins, earnings quality 22% weight
Valuation
82
Strong
Cheap vs sector & own history 24% weight
Growth
39
Weak
Sales & profit trajectory 9% weight
Financial Health
84
Strong
Solvency, leverage, coverage 9% weight
Momentum
18
Poor
Trend strength, vol-adjusted 12% weight
Ownership
44
Weak
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 58.3%

Weaknesses

1
  • The company has delivered a poor sales growth of 2.39% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallBearish775
OscillatorsBullish072
Moving AveragesStrong Bearish703

Key readings

RSI (14)
50.14
Neutral
MACD (12,26,9)
−11.78
Bullish
SMA (50)
3,874.48
Bearish
SMA (200)
4,521.76
Bearish

As of

Analyst Rating

Based on 5 analysts
BUY80%

4 of 5 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
4
80%
HOLD
1
20%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+2.28%
5Y+2.39%
3Y+1.29%
1Y+10.48%
TTM+11.75%

Net profit

Net profit growth by window
10Y+9.00%
5Y+7.71%
3Y+4.98%
1Y−5.99%
TTM+2.26%

Operating cash flow

Operating cash flow growth by window
10Y+10.87%
5Y+17.78%
3Y+39.58%
1Y+46.67%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+14.35 pp
5Y+4.07 pp
3Y+2.51 pp
1Y+3.34 pp
TTM+2.39 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,966 Cr
Mar 2018₹1,969 Cr
Mar 2019₹2,082 Cr
Mar 2020₹2,152 Cr
Mar 2021₹2,239 Cr
Mar 2022₹2,611 Cr
Mar 2023₹2,425 Cr
Mar 2024₹2,193 Cr
Mar 2025₹2,281 Cr
Mar 2026₹2,520 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹337 Cr
Mar 2018₹360 Cr
Mar 2019₹429 Cr
Mar 2020₹509 Cr
Mar 2021₹498 Cr
Mar 2022₹613 Cr
Mar 2023₹624 Cr
Mar 2024₹551 Cr
Mar 2025₹768 Cr
Mar 2026₹722 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹230 Cr −47.9% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 19 Nov 2026
AI opinion · based on fundamentals
Risk medium

Pfizer Ltd trades at ₹3,850.3 as of 2026-11-19 with a market cap of ₹17,614.25 crore, a PE of 20.5x, and a near-zero debt-to-equity ratio of 0.02. The company shows improving TTM profit growth of 13% but carries a legacy of sluggish revenue expansion at just 2% CAGR over five years, while the stock has declined 23% over the past one year.

Bull Case 7
  • Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.02, providing significant financial flexibility and resilience against economic downturns.
  • ROCE stands at 22.94%, indicating efficient deployment of capital and strong underlying business economics.
  • ROE of 17.19% (current) with a consistent 10-year average of 17%, reflecting durable profitability and steady return generation for shareholders.
  • Healthy dividend payout ratio of 58.3% combined with a dividend yield of 1.95%, offering meaningful income to investors at the current price of ₹3,850.3.
  • TTM profit growth has accelerated to 13%, meaningfully above the 3-year compounded profit growth of 8% and the 5-year rate of 9%, suggesting an improving earnings trajectory.
  • TTM sales growth of 12% marks a sharp uptick compared to the 3-year compounded sales growth of just 1% and the 5-year rate of 2%, pointing to a potential inflection in revenue momentum.
  • 10-year compounded profit growth of 10% has consistently outpaced the 10-year compounded sales growth of 2%, demonstrating sustained margin expansion and operating leverage over a long period.
Bear Case 7
  • Five-year compounded sales growth of only 2% highlights chronic top-line stagnation and limited ability to scale revenue over extended periods.
  • The stock has delivered a 1-year return of -23% and a negative 5-year CAGR of -5%, significantly destroying shareholder value over both short and medium horizons.
  • Even over a 3-year period, the stock CAGR is -2%, indicating the underperformance is not merely a short-term blip but a sustained trend.
  • A price-to-book ratio of 4.02x is relatively elevated for a company growing sales at only 2% compounded over five years, raising questions about valuation support.
  • The 10-year stock CAGR of 8% trails the 10-year compounded profit growth of 10%, suggesting the market has progressively de-rated the stock's earnings multiple over the long term.
  • Three-year compounded sales growth of just 1% is even weaker than the 5-year figure of 2%, indicating revenue growth decelerated further in recent years before the latest TTM uptick.
  • PE of 20.5x on an EPS of ₹187.85, while not extreme, demands sustained earnings growth to justify — any reversion in the TTM profit growth trend from 13% back toward the 3-year average of 8% could pressure the multiple.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

22h ago

TL;DR: Pfizer Ltd delivered a strong Q2FY27 headline with net profit up 65.7%, though stripping out the ₹132.06 crore one-time gain from the Minipress XL sale, core pre-tax profit growth was a more modest 13.86% YoY. Rising expenses and the discontinuation of Minipress XL bear watching as potential drags on future earnings. The underlying business remains healthy with steady revenue growth, but investors should monitor whether core profitability momentum sustains without non-recurring items.

Headwinds 3
  • Profit boost is non-recurring Nov 3

    The 65.7% net profit surge to ₹313.25 crore was primarily driven by a one-time exceptional gain of ₹132.06 crore from the Minipress XL divestiture, which will not repeat in future quarters.

  • Rising operational expenses Nov 3

    Total expenses increased to ₹483.2 crore in Q2FY27 from ₹428.82 crore a year ago, reflecting higher operational costs associated with business restructuring.

  • Minipress XL discontinued Nov 3

    Pfizer Ltd is discontinuing manufacture of Minipress XL from September 7, 2026, removing a product line from its portfolio following the sale to parent entity Pfizer Inc USA.

Positives 3
  • Q2 net profit surges 65.7% Nov 3

    Pfizer reported Q2FY27 net profit of ₹313.25 crore, up 65.7% YoY from ₹189 crore, while total income rose to ₹774.19 crore from ₹684.19 crore.

  • Core PBT up 13.86% YoY Nov 3

    Profit before tax and exceptional items grew 13.86% to ₹290.77 crore from ₹255.37 crore, indicating solid underlying operational improvement beyond the one-time gain.

  • Share price jumps 3.37% Nov 3

    Pfizer shares closed 3.37% higher at ₹3,760.50 on the BSE following the Q2 results announcement, reflecting investor confidence in the quarterly performance.

Quarterly Results

₹ Cr
PFIZER quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
575
540
547
563
589
538
592
603
642
645
629
653
727
Expenses
393
387
357
385
399
392
364
393
412
417
393
406
466
Operating Profit
183
153
189
177
189
146
228
210
230
228
236
248
261
OPM %
32%
28%
35%
32%
32%
27%
38%
35%
36%
35%
38%
38%
36%
Other Income
36
35.85
75
42
43
43
217
67
42
−20
40.72
45
47.33
Interest
3
3
7
2
2
2
3
3
2
2
2
1
3.35
Depreciation
15
18
14
15
15
15
16
14
14
14
15
14
14.41
Exceptional Items
—
7.95
—
—
—
—
—
—
—
—
9.04
—
132
PBT
201
176
244
203
215
172
426
260
255
192
269
277
423
Tax %
26%
26%
27%
26%
26%
26%
22%
26%
26%
26%
26%
26%
26%
Net Profit
149
130
179
151
158
128
331
192
189
142
200
204
313
EPS (₹)
32.56
28.41
39.10
32.94
34.61
27.89
72.34
41.91
41.32
31.00
43.68
44.70
68.47
YoY Sales growth
−10
−13
−5
6
2
0
8
7
9
20
6
8
13

Profit & Loss

₹ Cr
PFIZER profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,853
2,012
1,966
1,969
2,082
2,152
2,239
2,611
2,425
2,193
2,281
2,520
2,654
Expenses
1,438
1,579
1,616
1,468
1,516
1,578
1,526
1,775
1,616
1,555
1,540
1,615
1,681
Operating Profit
414
433
350
501
566
574
712
836
809
638
742
904
973
OPM %
22%
22%
18%
25%
27%
27%
32%
32%
33%
29%
33%
36%
37%
Other Income
44
97
232
114
167
183
81
63
101
185
344
188
254
Interest
2
1
2
0.42
1.29
11
15
10.49
13
15
8
9.48
9
Depreciation
250
58
63
66
71
103
109
115
106
62
61
58
58
Exceptional Items
—
—
—
—
—
—
—
—
33
—
—
−49.16
—
PBT
207
470
517
548
660
642
669
773
824
746
1,016
976
1,160
Tax %
66%
35%
35%
34%
35%
21%
26%
21%
24%
26%
24%
26%
—
Net Profit
70
305
337
360
429
509
498
613
624
551
768
722
859
EPS (₹)
15.26
66.67
73.62
78.71
93.79
111.29
108.77
133.90
136.38
120.52
167.79
157.92
187.85
Div. Payout %
82%
22%
27%
25%
24%
297%
32%
26%
29%
29%
98%
48%
—
Sales growth
67
9
−2
0
6
3
4
17
−7
−10
4
10
12

Balance Sheet

₹ Cr
PFIZER balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
46
46
46
46
46
46
46
46
46
46
46
46
46
Reserves
1,927
2,118
2,373
2,637
2,966
3,350
2,347
2,819
3,162
3,550
4,172
4,157
4,340
Borrowings
2
2
2
2
2
2
63
39
41
40
108
70
197
Other Liabilities
638
722
840
1,004
926
1,007
810
997
752
593
585
649
711
Total Liabilities
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922
5,293
Fixed Assets
944
925
902
950
886
973
894
869
749
713
724
678
804
CWIP
13
3
15
1
0
1
3
1
8
0
8
20
31
Investments
43
37
0
0
0
0
0
0
0
0
0
0
0
Other Assets
1,614
1,923
2,343
2,739
3,054
3,432
2,369
3,030
3,244
3,516
4,180
4,224
4,457
Total Assets
2,614
2,888
3,261
3,690
3,940
4,405
3,266
3,901
4,001
4,229
4,911
4,922
5,293

Cash Flow

₹ Cr
PFIZER cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
113
345
329
332
98
323
427
667
356
257
660
968
Investing
68
−701
−250
−238
35
1,530
−469
−575
−36
54
−71
−562
Financing
−1
−62
−83
−110
−110
−164
−1,571
−181
−346
−235
−205
−798
Net Cash Flow
181
−417
−3
−17
23
1,690
−1,613
−88
−26
75
383
−392
Free Cash Flow
93
398
394
262
125
343
410
654
292
291
783
944
CFO/EBITDA
62
120
146
105
59
93
89
107
81
64
110
105

Ratios

PFIZER financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
32
26
20
29
30
29
18
20
23
31
31
26
Inventory Days
191
167
148
147
189
198
199
173
175
200
214
195
Days Payable
165
157
178
245
213
197
130
102
91
77
68
89
Cash Conversion Cycle
58
36
−10
−69
6
31
87
91
107
154
177
132
Working Capital Days
7
−9
−47
−57
−16
−8
3
−14
1
24
23
9
ROCE %
24%
22%
17%
21%
23%
20%
23%
29%
26%
22%
21%
24%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Pfizer insights

65 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 63.92%
  • DIIs 17.52%
  • Public 12.20%
  • Others 4.72%
  • FIIs 1.63%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Pfizer

What does Pfizer Ltd do?
Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors…
Where is Pfizer Ltd (PFIZER) listed?
Pfizer Ltd trades as PFIZER on the NSE and under code 500680 on the BSE.
Which sector does Pfizer Ltd belong to?
Pfizer Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Pfizer Ltd?
Pfizer Ltd has a market capitalisation of ₹17,640 Cr as of 20 Nov 2026, which places it in the Smallcap band.
What is the PE ratio of Pfizer Ltd?
Pfizer Ltd trades at a PE ratio of 20.53 as of 20 Nov 2026, on earnings per share of ₹187.85, against a book value of ₹958.74 per share.
What is the 52-week high and low of Pfizer Ltd?
Over the last 52 weeks Pfizer Ltd has traded between ₹3,589 and ₹5,257 as of 20 Nov 2026.
Does Pfizer Ltd pay dividends?
Pfizer Ltd has a dividend yield of 1.95%.
What is the Return on Equity (ROE) of Pfizer Ltd?
Pfizer Ltd reported a return on equity of 18.00%. Its debt-to-equity ratio is 0.04.

Company Information

Pfizer Ltd is engaged in manufacturing, marketing, trading and export of pharmaceutical products. It manufactures products through its own facility and also has various independent contract/ third party manufacturers based across the country and sells its products through independent distributors primarily in India. It is the 3rd largest multinational pharmaceutical company in India.

CEO Ms. Meenakshi Nevatia
Employees 1,598
Listed 28 Apr 1999
Face Value ₹10
Shares Outstanding 4,57,47,732

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/PFIZER.md for Pfizer Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More